A novel tumor-specific gene therapy for bladder cancer

Chong-Xian Pan, K. S. Koeneman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Gene therapy has been successfully used to treat genetic diseases. Currently, much investigation involves the role of gene therapy in malignant tumors. One problem associated with the retroviral system used for gene therapy is its non-specificity. Herein a vector delivery system is described, using human telomerase reverse transcriptase (hTRT) promotor, which can specifically affect telomerase-positive tumor cells while sparing nearby telomerase-negative cells. By combining a self-containing Cre/loxP site-specific recombination system into the design, this vector will destroy telomerase-positive, p53-negative tumor cells, while sparing normal cells which are telomerase-positive with wild type p53 (such as activated lymphocytes). This vector design appears especially suited to bladder transitional cell carcinoma, because of easy access transurethrally and high rate of local recurrence, and biologically secondary to high proportion of telomerase activity and p53 dysfunction.

Original languageEnglish (US)
Pages (from-to)130-135
Number of pages6
JournalMedical Hypotheses
Volume53
Issue number2
DOIs
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

Telomerase
Urinary Bladder Neoplasms
Genetic Therapy
Neoplasms
Inborn Genetic Diseases
Transitional Cell Carcinoma
Genetic Recombination
Urinary Bladder
Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Developmental Biology
  • Medicine(all)
  • Drug Discovery

Cite this

A novel tumor-specific gene therapy for bladder cancer. / Pan, Chong-Xian; Koeneman, K. S.

In: Medical Hypotheses, Vol. 53, No. 2, 08.1999, p. 130-135.

Research output: Contribution to journalArticle

Pan, Chong-Xian ; Koeneman, K. S. / A novel tumor-specific gene therapy for bladder cancer. In: Medical Hypotheses. 1999 ; Vol. 53, No. 2. pp. 130-135.
@article{d96692ced7e6431abccbb4d6b0a24192,
title = "A novel tumor-specific gene therapy for bladder cancer",
abstract = "Gene therapy has been successfully used to treat genetic diseases. Currently, much investigation involves the role of gene therapy in malignant tumors. One problem associated with the retroviral system used for gene therapy is its non-specificity. Herein a vector delivery system is described, using human telomerase reverse transcriptase (hTRT) promotor, which can specifically affect telomerase-positive tumor cells while sparing nearby telomerase-negative cells. By combining a self-containing Cre/loxP site-specific recombination system into the design, this vector will destroy telomerase-positive, p53-negative tumor cells, while sparing normal cells which are telomerase-positive with wild type p53 (such as activated lymphocytes). This vector design appears especially suited to bladder transitional cell carcinoma, because of easy access transurethrally and high rate of local recurrence, and biologically secondary to high proportion of telomerase activity and p53 dysfunction.",
author = "Chong-Xian Pan and Koeneman, {K. S.}",
year = "1999",
month = "8",
doi = "10.1054/mehy.1998.0731",
language = "English (US)",
volume = "53",
pages = "130--135",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - A novel tumor-specific gene therapy for bladder cancer

AU - Pan, Chong-Xian

AU - Koeneman, K. S.

PY - 1999/8

Y1 - 1999/8

N2 - Gene therapy has been successfully used to treat genetic diseases. Currently, much investigation involves the role of gene therapy in malignant tumors. One problem associated with the retroviral system used for gene therapy is its non-specificity. Herein a vector delivery system is described, using human telomerase reverse transcriptase (hTRT) promotor, which can specifically affect telomerase-positive tumor cells while sparing nearby telomerase-negative cells. By combining a self-containing Cre/loxP site-specific recombination system into the design, this vector will destroy telomerase-positive, p53-negative tumor cells, while sparing normal cells which are telomerase-positive with wild type p53 (such as activated lymphocytes). This vector design appears especially suited to bladder transitional cell carcinoma, because of easy access transurethrally and high rate of local recurrence, and biologically secondary to high proportion of telomerase activity and p53 dysfunction.

AB - Gene therapy has been successfully used to treat genetic diseases. Currently, much investigation involves the role of gene therapy in malignant tumors. One problem associated with the retroviral system used for gene therapy is its non-specificity. Herein a vector delivery system is described, using human telomerase reverse transcriptase (hTRT) promotor, which can specifically affect telomerase-positive tumor cells while sparing nearby telomerase-negative cells. By combining a self-containing Cre/loxP site-specific recombination system into the design, this vector will destroy telomerase-positive, p53-negative tumor cells, while sparing normal cells which are telomerase-positive with wild type p53 (such as activated lymphocytes). This vector design appears especially suited to bladder transitional cell carcinoma, because of easy access transurethrally and high rate of local recurrence, and biologically secondary to high proportion of telomerase activity and p53 dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0032854027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032854027&partnerID=8YFLogxK

U2 - 10.1054/mehy.1998.0731

DO - 10.1054/mehy.1998.0731

M3 - Article

C2 - 10532707

AN - SCOPUS:0032854027

VL - 53

SP - 130

EP - 135

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 2

ER -